Baiji Shenzhou submitted an IPO application on the Science and Technology Board, more than 50 products to help the capital road!

According to the information released by the Shanghai Stock Exchange, Baiji Shenzhou has submitted an IPO application to the Company and was accepted on January 29.
according to the prospecto, Baiji Shenzhou's joint sponsor (the main underwriter) for the listing is COG and Goldman Sachs, with a proposed capital raising of Rmb20bn.
it is worth mentioning that Baiji Shenzhou was listed on the NASDAQ Stock Exchange in 2016 and landed on the Hong Kong Stock Exchange in 2018.
the IPO on the Board means that Baiji Shenzhou is expected to become a listed biopharmaceutical company on NASDAQ, HKEx and Kotseng Board.
in the pharmaceutical Mission Hills micro-signal reply "Baiji Shenzhou" can download Baiji Shenzhou Science and Technology Board IPO prospectos.
Screenshot Source: Resources: Founded in 2010, Baiji Shenzhou is a global, commercial biotech company focused on research, development, production and commercialization of innovative pharmaceuticals.
Over the past decade, the company has grown into a global biotech company with all-round integration of early drug discovery, preclinical trials, clinical research, large-scale high-quality drug production and science-based commercialization capabilities.
the prospectine, through the combination of independent research and development and authorized cooperation, Baiji Shenzhou has now established a rich product portfolio.
currently, the company has 47 commercial and clinical stage candidates, including 7 commercial stage drugs, 5 declared market candidates and 35 clinical stage candidates.
addition, the company has more than 10 preclinical research products.
photo source: 123RF2 independent research and development of new drugs approved for market, 22 new drugs or new adaptive drug listing applications have been submitted for innovation and research and development is the focus of continued investment in Baiji Shenzhou.
Since its inception, the company has entered clinical trials or commercialization of 11 self-developed drugs, of which 2 products have been approved for market, respectively, BTK small molecule inhibitor Bai Yueze (Zebutini capsule) and anti-PD-1 monoanti-Benzean (Tyrelli pearl monoantigen injection).
, Zebtinib accelerated approval in the U.S. in 2019 for the treatment of adult cell lymphoma (MCL) patients, the first new drug approved by the FDA in China.
in China, Zebtinib has been approved in 2020 to treat adult MCL patients and adult chronic lymphocytic leukemia (CLL)/small lymphocyte lymphoma (SLL) patients, both of which have been included in the new China National Health Insurance Directory.
Reilly-Zhudan resistance has been approved in China for three adaptations, including the treatment of patients with relapsed or refractic classic Hodgkin's lymphoma (cHL) who have underwent at least second-line system chemotherapy, and the failure of highly expressive platinum-containing chemotherapy in PD-L1, including new or complementary chemotherapy1 Patients with localized advanced or metastatic urethratic cortical cancer (UC) who progressed within 2 months, as well as two chemotherapy programs for the treatment of patients with first-line advanced squamous non-small cell lung cancer (NSCLC), of which cHL and urethra skin cancer adaptation have been included in the new version of China's national health insurance directory.
In addition to the five adaptations approved in the United States and China, Baiji Shenzhou has submitted 22 applications for the listing of new drugs or new adaptives in 17 countries and regions around the world and is expected to be approved in 2021 and beyond.
Among them, Zebtini has submitted 19 applications for the listing of new drugs and new adaptive diseases, covering 43 countries around the world, and has been accepted in China, the European Union, Australia, Canada, Israel and other countries and regions;
Screenshot Source: Resources: In addition, Parp1 and PARP2 inhibitors Pamiparib, developed by Baiji Shenzhou, have submitted a new drug listing application in China and are included in the priority review for the treatment of patients with advanced ovarian, fallopian or primary peritonal cancer who have received at least two lines of chemotherapy in the past, carrying pathogenic or suspected pathogenic germ BRCA mutations.
established commercial cooperation with more than 10 companies such as Novarma and Amjin, in addition to independent research and development, Baiji Shenzhou is also promoting the development and commercialization of independent research and development products in the world through external authorization.
In January 2021, for example, Novartis and Baiji Shenzhou just struck a $2.2 billion partnership to jointly develop, produce and commercialize reilly monoliths in North America, Japan, the European Union and six other European countries.
, according to the prospecto, the partnership is by far the highest down payment and total amount of the transaction authorized for Chinese pharmaceutical authorized transactions.